CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that redirects patient T cells via CD3 to kill CD20+ malignant B cells.
A CD20×CD3 bispecific monoclonal antibody that binds CD3 on T cells and CD20 on B cells, crosslinking them to activate and redirect cytotoxic T cells to kill CD20-positive malignant B cells.
YES
DIRECT
Bispecific T-cell engager binds CD20 on target cells and CD3 on T cells, crosslinking and activating T cells to kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.
CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that redirects patient T cells via CD3 to kill CD20+ malignant B cells.
A CD20×CD3 bispecific monoclonal antibody that binds CD3 on T cells and CD20 on B cells, crosslinking them to activate and redirect cytotoxic T cells to kill CD20-positive malignant B cells.
NO
INDIRECT
CD3+ T cells are engaged, not killed; glofitamab crosslinks CD3 on T cells to CD20 on B cells, activating T-cell cytotoxicity (perforin/granzyme) against CD20+ cells.
Type II anti‑CD20 monoclonal antibody that depletes B cells and enhances ADCC; used as pretreatment to reduce tumor burden and mitigate CRS risk.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells; enhanced Fc glycosylation increases FcγRIIIa affinity to boost ADCC/ADCP, and type II engagement triggers direct, caspase‑independent apoptosis (with limited CDC), resulting in potent B‑cell depletion.
YES
DIRECT
Obinutuzumab binds CD20 on B cells; its Fc is glycoengineered to enhance FcγRIIIa engagement, driving ADCC/ADCP by NK cells/macrophages, and type II binding induces direct caspase‑independent apoptosis (with limited CDC), leading to B‑cell killing.
Type II anti‑CD20 monoclonal antibody that depletes B cells and enhances ADCC; used as pretreatment to reduce tumor burden and mitigate CRS risk.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells; enhanced Fc glycosylation increases FcγRIIIa affinity to boost ADCC/ADCP, and type II engagement triggers direct, caspase‑independent apoptosis (with limited CDC), resulting in potent B‑cell depletion.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages CD16a (FcγRIIIa) on NK cells/macrophages to trigger ADCC/ADCP and apoptosis of CD20+ targets. CD16a-expressing cells act as effectors and are not killed.
Type II anti‑CD20 monoclonal antibody that depletes B cells and enhances ADCC; used as pretreatment to reduce tumor burden and mitigate CRS risk.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells; enhanced Fc glycosylation increases FcγRIIIa affinity to boost ADCC/ADCP, and type II engagement triggers direct, caspase‑independent apoptosis (with limited CDC), resulting in potent B‑cell depletion.
NO
INDIRECT
Obinutuzumab targets CD20 on B cells; its Fc engages Fcγ receptors on immune effectors to mediate ADCC/ADCP and induces direct apoptosis of CD20+ B cells. CD16b-expressing cells (e.g., neutrophils) act as effectors, not targets, and are not directly killed by the drug.